Finding Healthcare Investors: PE, Family Offices, Strategics, VC, Physicians and Lenders
Healthcare capital comes from six sources: private equity, family offices, strategic buyers, venture capital and angels, physician investors and lenders. Match the source to the transaction. A control sale goes to PE or a strategic. A minority growth round or partial recap goes to a family office or physicians. Healthtech goes to VC. A cash-flow-backed expansion goes to a lender. The rest of this guide shows how to pick between them, where to find the names and how to compare the offers on one sheet.
Data current as of November 20, 2026. Each sourced figure links to its source document and names the population and period. Figures labeled our arithmetic are calculated from those sources.
Investors keep coming because the spending base keeps growing. The CMS National Health Expenditure fact sheet reports that US spending on physician and clinical services topped $1 trillion in 2024. CMS projects that category to grow 5.5% a year on average over 2025 to 2034. Your payer mix decides how much of that growth reaches your practice. In the same 2024 data, Medicare accounted for 21% of total health spending and private health insurance for 31%.
The 6 Investor Types Compared: Control, Capital Form and Horizon
| Investor | What they buy | Control | Horizon | What sets the timeline | Best fit | Watch for |
|---|---|---|---|---|---|---|
| Private equity (platform or add-on) | Majority equity, usually with seller rollover | Majority and board | Fixed fund life, exit by resale | QoE, investment committee | Scalable specialties with add-on runway | Your rollover value depends on the next buyer |
| Family office | Minority or majority equity, structured equity, some private debt | Negotiable | Set by the family for direct deals, by the vehicle for fund or SPV deals | The office's own approval process | Growth rounds, partial recaps, long holds | Mandates and healthcare depth differ widely from office to office |
| Strategic (hospital system, large provider group, health plan) | Full acquisition or employment model | Full | No fixed exit date, though strategics do divest units | Committee and integration planning | Practices that add market share or fill service lines | You become an employee, and referral rules shape how physician pay is set |
| Venture capital and angels | Minority preferred equity | Board seat, protective provisions | Fund life, exit by sale or IPO | Partner meeting | Healthtech, devices, diagnostics, biotech | Liquidation preferences and dilution in each round |
| Physician investors | Small minority checks pooled in a syndicate | None individually | Long, yield-focused | Collecting many checks to a close | ASCs, imaging, real estate, de novo sites | Referral rules and securities offering rules |
| Lenders (bank, SBA, private credit) | Senior or unitranche debt | Covenants, guarantees | Loan term | Credit underwriting | Stable EBITDA, acquisitions, dividend recaps | A covenant breach shifts control to the lender |
Start With Your Goal
| Your goal | Call first | Call second | Usually a poor fit |
|---|---|---|---|
| Full exit within a year | PE platform in your specialty, hospital system | Large provider group, health plan | Physician syndicate, VC |
| Take some cash off the table and keep control | Direct-investing family office | Lender (dividend recap) | Strategic |
| Fund new sites without giving up equity | Bank or SBA lender | Private credit, family office structured equity | VC |
| Build an ASC, imaging center or real estate project | Physician syndicate, family office | Lender for the build-out | VC |
| Scale a healthtech product | Healthcare VC fund | Corporate venture arm, family office | Bank lender |
| Fix payer rates or administrative load | Hospital system, PE platform with contracting scale | Health plan | Lender (capital alone does not change contracts) |
Seven Questions Before You Build a List
- [ ] Is the business a cash-flowing provider or a high-growth technology company? Providers are valued on EBITDA. Technology companies are valued on growth and go to VC.
- [ ] Do you want to keep control? If not, look at PE or a strategic. If so, look at a family office, physician investors or debt.
- [ ] Does the business produce steady cash flow after capex? If it does, get term sheets from two or three lenders before you sell equity. Compare the full package: amount, rate, fees, covenants, personal guarantees and what happens at maturity.
- [ ] Do any target investors refer patients to you? If so, referral rules shape the structure before price does.
- [ ] Which states do you operate in? Some states review healthcare transactions before closing, which can affect timing or structure. Raise it with your own attorney and build it into the timeline from day one.
- [ ] Who buys the business after this investor? PE and VC funds exit by selling. A strategic has no set exit date but can divest. A family office's exit plan depends on how it invests.
- [ ] What problem is the capital solving? Payer contracting, equipment, new sites and administrative load each point to a different investor.
The last question narrows the field fastest. In the AMA Policy Research Perspective, Physician Practice Characteristics in 2024, physicians who had sold their practices in the prior 10 years to a hospital, PE firm or insurer rated these reasons as important or very important:
| Reason for selling (AMA 2024 survey, physicians who sold in the prior 10 years) | Share rating it important or very important | Investors that can address it, depending on buyer and terms |
|---|---|---|
| Better negotiate higher payment rates with payers | 70.8% | Hospital systems, large provider groups, PE platforms with contracting scale |
| Improve access to costly resources | 64.9% | Strategics, PE platforms, family offices, lenders |
| Better manage payers' regulatory and administrative requirements | 63.6% | Strategics, PE platforms with shared billing and compliance teams |
Ownership alone does not change a payer contract. A larger owner helps only if its contracts cover your market and your practice moves onto them. Ask each buyer three questions. Which payer contracts do you hold in my market? Will my practice move onto them, and when? Which billing, credentialing and compliance functions will you take over? Family office equity and debt address the second reason only.
Where Independent Practices Still Sit: Specialty and Size
Buyer interest follows the remaining pool of independent physicians. The AMA press release on the 2024 Physician Practice Benchmark Survey reports that private practices now account for less than half of physicians in most specialties. The exceptions are surgical.
| Specialty | Share of physicians in private practice (AMA press release, 2024 survey) |
|---|---|
| Ophthalmology | 70.4% |
| Orthopedic surgery | 54.0% |
| Other surgical subspecialties | 51.2% |
| Radiology | 46.9% |
| Cardiology | 30.7% |
Size shapes the investor too. The AMA's 2024 report found that 49.2 percent of physicians in private practice work in practices with fewer than five physicians, and only 11.8 percent in practices of 50 or more. Groups that small are add-on candidates or debt borrowers. Few can anchor a new PE platform. Across all practice types, the same report puts the share of physicians in practices of 10 or fewer at 47.4 percent in 2024, down from 61.4 percent in 2012. In the AMA's words, it was "the first time this share has dipped below 50 percent."
Private Equity: 119 of 148 Tracked Outpatient Deals in 2025 Were Add-Ons
PE owns a small but rising share of physician practices. The AMA press release reports that 6.5 percent of physicians described their practice as PE-owned in 2024, up from about 4.5 percent in both 2020 and 2022. In the same survey, 34.5 percent described their practice as hospital-owned, about five times the PE share (our arithmetic: 34.5 ÷ 6.5 = 5.3).
Most of PE's position is recent. The AMA's 2024 report found that about 38 percent of physicians in PE-owned practices had been acquired in the prior five years, against about 10 percent in hospital-owned practices. Only 17.1 percent of physicians in PE-owned practices were acquired before 2015, compared with 47.2 percent in hospital-owned practices.
Most practices enter PE as an add-on, not a platform. Becker's ASC Review, reporting Private Equity Stakeholder Project (PESP) data, counted 148 deals involving outpatient care providers in calendar 2025. The count covers outpatient providers only and reflects PESP's own tracking, so it is not a total of all PE healthcare activity. Of those, 119 were add-ons, or 80.4 percent (our arithmetic: 119 ÷ 148). By subsector, dermatology led with 24 deals, eye care had 22 and oncology had 9.
How to use this in your search:
- Target platforms before funds. The fund sets strategy, but the platform's CEO and development team source and close add-ons in your specialty and region.
- Use announcements as a map. Every add-on press release names a platform, its sponsor and its geography. Ten announcements in your specialty give you a working buyer list. Track platform, sponsor, states, date and the platform's head of development.
- Pitch platform-scale businesses to funds directly. A practice large enough to anchor a new platform belongs in front of the fund's healthcare partners.
- Price the rollover, not just the headline. Add-on sellers usually roll equity into the platform. That stake is worth what the next buyer pays, less the platform's debt. Private Equity Physician Roll-Ups covers how the model pays each party.
Diligence on the Sponsor's Clock
Your rollover rides the platform's next exit, so find out where the platform sits in its life before you sign. The date the sponsor bought the platform does not tell you when it will sell. Ask for the facts directly.
| Ask the sponsor | Effect on your rollover |
|---|---|
| Which fund owns the platform, and what is that fund's vintage year and remaining term? | An older fund has less time left to hold and more pressure to return capital |
| When did the sponsor acquire the platform, and what hold period did it underwrite? | Shows whether your rollover is entering early or late in the plan |
| Is a sale, recapitalization or continuation vehicle planned or under discussion? | A near-term exit can value your rollover before your practice has been integrated |
| If a continuation vehicle is used, can rollover holders choose to sell or roll again? | Decides whether you get liquidity or another hold period |
| How much debt does the platform carry, and where does rollover equity rank? | Platform debt is paid before your equity at the exit |
| Do rollover holders have tag-along rights and information rights? | Decides whether you sell on the same terms as the sponsor and see results in the meantime |
Ask two physicians who sold into the platform earlier how their rollover has been reported and valued since closing.
Worked Example: Control Sale vs Minority Recap
Simplified transaction model, hypothetical numbers, our arithmetic. The multiples are illustrative assumptions, not market data. The lower family office multiple reflects an assumed minority discount. All figures are gross of taxes, transaction fees and working capital adjustments.
Assumptions: - An orthopedic group with $2.5 million of EBITDA and $2.5 million of existing debt - PE control offer at 9.0x EBITDA for 100 percent. Debt is repaid from proceeds at closing. Owners roll 20 percent of equity value into the platform. - Family office minority offer at 7.0x EBITDA for 30 percent of the equity, bought from the owners. The debt stays on the practice.
| PE control sale | Family office minority recap | |
|---|---|---|
| Enterprise value | $2.5M × 9.0 = $22.5M | $2.5M × 7.0 = $17.5M |
| Equity value (enterprise value less $2.5M debt) | $20.0M | $15.0M |
| Cash to owners at close | 80% × $20.0M = $16.0M | 30% × $15.0M = $4.5M |
| Equity owners keep | $4.0M of platform equity (20% × $20.0M) | 70% of the practice, $10.5M at the deal price |
| Debt remaining on the practice | None (repaid at close) | $2.5M |
| Who controls the next sale | The sponsor | The owners |
| What the retained stake depends on | Platform performance, platform debt and the sponsor's exit | Your own performance and exit timing |
The PE offer pays $11.5 million more cash at close ($16.0M less $4.5M). The recap keeps $6.5 million more equity on paper ($10.5M less $4.0M) plus control. The retained $10.5 million is marked at a minority price. A later control sale would likely price higher. The right answer turns on how much cash the owners need now and whether they trust their own growth plan more than the platform's.
Family Offices: Match the Office's Structure to Your Deal
A single family office invests one family's capital. How it invests matters more than the label. An office writing direct checks from the family's balance sheet answers to no outside limited partners. That gives it room to hold a healthcare business for as long as the family chooses, take a minority stake or structure a partial recap a PE fund would decline. Room is not the same as appetite. Its own investment policy, committee and risk limits still decide what it will do. An office that invests through its own fund, an SPV with outside capital or co-investments alongside a sponsor takes on that vehicle's horizon and exit terms.
| How the office invests | Horizon | Typical position | Ask before the first meeting |
|---|---|---|---|
| Direct, from the family's balance sheet | Set by the family's policy | Minority or control | Who makes the final decision, and which approvals sit between you and that person |
| Through its own fund or an SPV with outside investors | The vehicle's term | Follows the vehicle documents | Fund or SPV term, target exit year, whether outside investors must approve |
| Co-investment alongside a PE sponsor | The sponsor's hold | Minority, behind the sponsor | Which sponsors it backs, and whether it ever leads |
| Multi-family office | Set by client mandates | Varies by client | Whether each client approves each deal |
Healthcare depth varies as much as structure. Some offices employ former hospital executives and clinicians and hold several healthcare companies. Others have never underwritten a payer contract and rely on outside advisors. Qualify each office on five points:
| Qualifier | Strong signal | Weak signal |
|---|---|---|
| How it invests | Direct deals with a named decision-maker | "We look at everything" with no closed healthcare deal to point to |
| Healthcare depth | Operators or clinicians on staff, prior healthcare holdings | Relies entirely on outside advisors |
| Position | States plainly whether it takes minority stakes | Asks for control late in the process |
| Check size | Gives a range and says whether it leads or follows | Will not name a range |
| Hold and exit | Describes a hold period and an exit route it has used before | No answer on how past deals ended |
Approach your two or three best-matched offices first, with a complete data package, before the deal goes wide. An office that sees a deal after twenty others have passed asks why. How Family Offices Invest in Healthcare covers structures and sector preferences. The healthcare data room checklist lists what to have ready before the first call.
Strategic Buyers: 34.5 Percent of Physicians Work in Hospital-Owned Practices
Hospitals have absorbed most of the shift away from private practice. The figures below come from the AMA's 2024 report and reflect how surveyed physicians described their practice ownership. Point changes are our arithmetic.
| Ownership measure (AMA survey) | 2012 | 2024 | Change |
|---|---|---|---|
| Physicians in private practice (wholly physician-owned) | 60.1% | 42.2% | down 17.9 points |
| Physicians in hospital-owned practices | 23.4% | 34.5% | up 11.1 points |
| Physicians employed by or contracted directly with a hospital | 5.6% | 12.2% | more than doubled |
| Physicians with an ownership stake in their practice | 53.2% | 35.4% | down 17.8 points |
Hospital systems are also consolidating among themselves. Becker's Hospital Review, reporting Kaufman Hall data, reported in 2026 that hospital M&A was on pace for its busiest year since the pandemic, citing Kaufman Hall data. The pace can change from quarter to quarter. Check Kaufman Hall's latest quarterly report for current figures before relying on the trend. A system integrating its own merger may have little room for a physician group. Check your target's deal calendar before you open talks.
Strategics buy differently from financial investors:
- They pay for fit. Service line gaps, market share and payer position drive the price as much as an EBITDA multiple.
- They build large groups. In the AMA's 2024 report, 31.3 percent of physicians in hospital-owned practices work in practices of 50 or more physicians.
- Physician pay is constrained. When employed physicians refer to the system, referral rules shape how their compensation is set. That limits how much value can move from purchase price into future pay.
- The approach goes through operations. Start with the service line VP or the physician enterprise president, not corporate development.
Health plans and large multi-site provider groups also buy practices. Their reasons differ by buyer and by deal. Some want network coverage in a market, some want primary care capacity for value-based contracts and some want a specialty they currently pay others for. Ask each one what role your practice would play in its model and how your physicians would be paid in that role.
Venture Capital and Angels: Healthtech, Devices and Life Sciences
VC funds buy minority preferred equity in businesses that can grow many times over and exit through a sale or IPO within the fund's life. That covers care delivery software, digital health, devices, diagnostics and biotech. VC funds do not price a mature practice on EBITDA.
| Stage | Typical source | What the investor needs to see |
|---|---|---|
| Pre-seed and seed | Angels, physician angels, angel groups, some family offices | Founding team, clinical problem, early prototype or pilot |
| Series A | Healthcare-focused VC funds | Early revenue or validated pilots, a defined buyer and payer |
| Growth | Larger VC funds, crossover funds, corporate venture arms of health systems and payers | Repeatable sales, reimbursement in place, unit economics |
Healthcare VC diligence turns on four questions:
- Who pays? A patient, an employer, a health plan or a health system. Each has a different sales cycle and budget.
- What is the regulatory path? Devices and some clinical software need FDA clearance or approval before revenue starts, and investors price that time.
- Is there a reimbursement path? A product without a billing code depends on direct contracts or on savings it can prove.
- What clinical evidence exists? Health system buyers ask for outcomes data, and investors price the time it takes to produce it.
Read the term sheet beyond the valuation. Liquidation preferences, board composition and protective provisions decide who gets paid and who decides if the company underperforms. Corporate venture arms bring distribution as well as capital, and they tie you to one strategic before you have chosen an acquirer.
Physician Investors: Map Referrals Before You Take a Check
Physicians are a natural investor base for ASCs, imaging centers, real estate and de novo clinics. They understand the clinical case, and many want income beyond clinical pay. The Medscape Physician Compensation Report 2025 press release, covering 2024 pay, reports average physician compensation up 3.6 percent. The press release also says 47 percent of surveyed physicians felt fairly paid and about 40 percent were seeking paid work outside their primary roles. These figures come from the press release summary, not the full report. The survey measures pay pressure, not willingness to invest. Use it as context for the pitch.
Fewer physicians own a practice than a decade ago. The AMA's 2024 report puts owners at 35.4 percent, employees at 57.5 percent and independent contractors at 7.1 percent. Employed physicians can still invest, but many have never read an operating agreement. Budget time to explain the structure.
High-risk area: physician investors and referrals. Two sets of rules shape every physician raise. Referral laws can limit which physicians may own part of a business they send patients to. Securities rules govern how you find, approach and sell to investors. Either can change the structure, the investor list or the timeline. Take these questions to your own healthcare and securities attorney before any outreach:
- Which prospective investors refer patients to the business, and does that rule any of them out?
- How should distributions be set so they follow capital invested and not referral volume?
- Which offering path fits our outreach plan, and what does it allow us to say and to whom?
- What disclosures and investor qualifications does that path require?
- Do any states where we operate add their own limits on physician ownership?
Our Healthcare Compliance Due Diligence guide and Raising Capital from Physician Investors cover the background.
Practical steps that make a physician raise close cleanly:
- [ ] Build a referral map first. For each prospective physician investor, record whether they refer to the business, how often and for which services. Diligence will ask for it, and it decides who can be in the syndicate.
- [ ] Tie returns to capital, not referrals. Distributions should follow capital invested. Structures where returns track referral volume are the ones regulators challenge.
- [ ] Decide early whether you will market publicly. Most physician syndicates are raised through existing relationships. That choice sets which offering path you use, so make it before any outreach goes beyond people you know.
- [ ] Screen your team before investors do. Check current and prospective employees and contractors against the HHS OIG List of Excluded Individuals and Entities. Investors will ask to see that screening.
- [ ] Set a minimum check and a closing date. A syndicate with a clear minimum, a fixed close and a lead investor committed early closes on schedule. One without them drifts.
Raising Capital from Physician Investors covers how physicians evaluate these deals. Capital Raising for Healthcare Companies covers offering mechanics.
Lenders: Price Debt Before You Sell Equity
Debt does not dilute ownership. Whether it costs less than equity depends on the full package, not the rate alone. Debt carries its own control. Covenants restrict distributions, acquisitions and further borrowing. Personal guarantees put owners' assets at risk. A breach hands the lender leverage over the business. The loan also has to be repaid or refinanced at maturity, on whatever terms the market offers then.
| Compare across lenders | What to ask for in writing |
|---|---|
| Capacity | Maximum amount, whether it is sized on trailing, adjusted or projected cash flow, which add-backs count, and whether ramp losses at new sites reduce it |
| Price | Rate, whether fixed or floating, upfront and unused-line fees, prepayment penalties |
| Covenants | Leverage and coverage tests, how EBITDA is defined for them, how often they are tested |
| Guarantees and collateral | Personal guarantees, spousal consent, liens on real estate or receivables |
| Amortization and maturity | Interest-only period, repayment schedule, balloon at maturity |
| Refinancing risk | What happens if rates rise or EBITDA falls before the loan must be refinanced |
| Lender type | Typical fit |
|---|---|
| Bank | Steady, documented cash flow, owners willing to guarantee |
| SBA 7(a) | Smaller practices and acquisitions. The SBA 7(a) program is the SBA's main small business loan program |
| Private credit | Acquisition plans and leverage levels banks decline, at higher cost |
| Asset-based lender | Businesses with large receivables or equipment bases |
Actual capacity, pricing and covenants come from each lender's underwriting of your numbers. Get at least two written term sheets before you compare debt with equity.
Worked Example: All Equity vs Debt Plus Equity
Simplified transaction model, hypothetical numbers, our arithmetic. A dermatology group has $3.0 million of EBITDA and needs $9.0 million to build four new sites.
Assumptions: - Pre-money enterprise value of 8.0x EBITDA, or $24.0 million. No existing debt, so pre-money equity value is also $24.0 million. - New capital is valued at par, so $9.0 million raised adds $9.0 million to enterprise value at closing - Senior debt at 9 percent, interest-only for three years. Fees, taxes and the tax deductibility of interest are ignored. - The four new sites lose a combined $1.0 million in year one while they ramp - Maintenance capex on existing sites is $0.3 million a year - All cash not spent on interest is distributed or retained pro rata to ownership, the same in both options
| Option A: all equity | Option B: senior debt plus family office equity | |
|---|---|---|
| Senior debt | $0 | $6.0M (2.0x EBITDA) |
| New equity | $9.0M | $3.0M |
| Post-money equity value | $24.0M + $9.0M = $33.0M | $24.0M + $9.0M less $6.0M = $27.0M |
| Investor stake | $9.0M ÷ $33.0M = 27.3% | $3.0M ÷ $27.0M = 11.1% |
| Owners' stake | 72.7% | 88.9% |
| Owners' equity value at close | 72.7% × $33.0M = $24.0M | 88.9% × $27.0M = $24.0M |
| Annual interest | $0 | $6.0M × 9% = $540,000 |
| Year-one cash before interest | $3.0M less $1.0M less $0.3M = $1.7M | $1.7M |
| Year-one interest coverage | n/a | $1.7M ÷ $0.54M = 3.1x |
Both options leave the owners with $24.0 million of value on day one. Option B keeps 16.2 more points of ownership. The owners pay for those points with $540,000 a year of interest, covenants and risk. Coverage measured on EBITDA alone reads 5.6x ($3.0M ÷ $0.54M). Ramp losses and capex cut it to 3.1x. Lenders define coverage differently, on EBITDA, adjusted EBITDA, fixed charges or total debt service, so ask each lender which measure it tests and rerun the numbers on that definition.
Year three, debt still at $6.0 million, enterprise value at 8.0x EBITDA, our arithmetic:
Assumptions for the table: cash before interest rises in a straight line from $1.7 million in year one to year-three EBITDA less $0.3 million of capex, so year two is the midpoint of years one and three. All of it is distributed each year. Distributions are summed without discounting, taxes or fees. Option A's owners receive 72.7 percent of that cash. Option B's owners receive 88.9 percent of what is left after interest. Three years of interest totals $1.62 million ($540,000 × 3), and Option B's owners bear 88.9 percent of it, or $1.44 million. In return they take 16.2 more points of every dollar distributed.
| Year-three enterprise value | Owners' value, Option A | Owners' value, Option B | Option B ahead on equity value | Three-year cash before interest | Option B ahead on distributions | Option B ahead in total |
|---|---|---|---|---|---|---|
| $36.0M (EBITDA $4.5M) | 72.7% × $36.0M = $26.2M | 88.9% × $30.0M = $26.7M | $0.5M | $1.7M + $2.95M + $4.2M = $8.85M | roughly even (16.2% × $8.85M = $1.43M, less $1.44M) | $0.5M |
| $48.0M (EBITDA $6.0M) | 72.7% × $48.0M = $34.9M | 88.9% × $42.0M = $37.3M | $2.4M | $1.7M + $3.7M + $5.7M = $11.1M | $0.4M (16.2% × $11.1M = $1.80M, less $1.44M) | $2.8M |
Under these assumptions debt comes out ahead in both cases, but the margin depends on the new sites. At $4.5 million of EBITDA Option B is only $0.5 million ahead, a thin return for three years of covenants and guarantees. Loan fees, taxes and working capital needs, which this model leaves out, would narrow that gap further and could erase it. At $6.0 million it is $2.8 million ahead. If EBITDA stays flat at $3.0 million and cash before interest stays at $1.7 million a year, the same arithmetic puts Option B about $2.1 million behind.
Now stress year one. If core EBITDA falls by a third to $2.0 million, cash before interest drops to $0.7 million ($2.0M less $1.0M less $0.3M). Coverage falls to 1.3x ($0.7M ÷ $0.54M) and leverage on core EBITDA rises to 3.0x ($6.0M ÷ $2.0M). That combination can trip a covenant while the new sites are still losing money. Run this test, ramp losses included, before you choose. Healthcare Debt Financing compares bank, SBA, private credit and asset-based terms.
What Each Investor Will Ask For
Have the package ready before the first call. Gaps found in diligence cost price or time.
| Item | PE | Family office | Strategic | VC | Physician syndicate | Lender |
|---|---|---|---|---|---|---|
| Three years of monthly financials | Yes | Yes | Yes | Revenue and burn | Summary | Yes |
| Quality of earnings report | Common, varies with deal size | Often | Often | Rarely | Rarely | For larger loans |
| Payer mix and top payer contracts | Yes | Yes | Yes | Reimbursement path | Summary | Yes |
| Provider roster, productivity and comp | Yes | Yes | Yes | Clinical team | Yes | Key-person detail |
| Compliance file (licensure, exclusion screening, billing audits) | Yes | Yes | Yes | Regulatory path | Yes | Yes |
| Growth plan with site-level economics | Yes | Yes | Service line fit | Market size and unit economics | Project budget | Debt service model |
| Referral map of investors | n/a | If physicians invest | n/a | If physicians invest | Yes | n/a |
For staffing and wage assumptions in the growth plan, the BLS Health Care and Social Assistance industry page carries current official employment and wage data. Investors will check your hiring plan against it.
Before You Sign a Term Sheet: Comparing Offers on One Page
Offers arrive in different shapes: cash plus rollover, a minority price, a loan with covenants. Put every offer on one sheet before you negotiate any of them. The worked examples above show the method. The control sale and the minority recap look $5.0 million apart on enterprise value ($22.5M vs $17.5M), but $11.5 million apart on cash at close and $6.5 million apart the other way on retained equity.
| Line on the comparison sheet | What to enter | What it tells you |
|---|---|---|
| Cash at close | Equity value × share sold, less debt repaid, fees and escrows | What you can actually spend or reinvest now |
| Retained equity and who controls it | Rollover or remaining stake, and whose exit it rides on | Whether your upside depends on your plan or a sponsor's |
| Debt left on the business | Balance, rate, annual interest, covenants, guarantees, maturity | The fixed cost and risk the retained equity carries |
| After-tax proceeds | Your tax advisor's model of rollover, asset vs stock and earnout terms | The number to compare, since structure changes net proceeds |
| Downside case | Cash and coverage with core EBITDA down a third, as in the debt example | Which offer still works if the year goes badly |
| Approvals to closing | Every committee, consent and review the investor named at the first meeting | A realistic closing date, not the hoped-for one |
| Fees to intermediaries | Who is paid, how much and on what basis | The true cost of the raise or sale |
Work the sheet in this order:
- [ ] Fill in every line for every offer. A blank line is a question to send back to the investor, not an assumption to make.
- [ ] Rank on cash at close and the downside case first. Headline multiples flatter offers that defer value into rollover or leave debt on the practice.
- [ ] Price retained equity at a discount you can defend. A minority stake or rollover marked at the deal price is a paper number until someone buys it.
- [ ] Check who is being paid to bring you the deal. Look up any firm or banker asking for a success fee on FINRA BrokerCheck, which shows registration and disclosure history for free. How to Choose a Healthcare Investment Banker covers who can be paid to sell a company or introduce investors.
- [ ] Flag structural issues before the term sheet, not after. Ownership structure, physician referrals and state transaction reviews can change the timeline or rule out an investor type. Assemble the deal structure file below early.
The Deal Structure File: What to Assemble Before Offers Arrive
Structure questions slow a deal most when the facts behind them are scattered. Put these items in one file before the first term sheet. It lets your advisors answer quickly and lets you see which offers carry the most open questions.
| File item | What goes in it | Offers it affects most |
|---|---|---|
| Ownership and entity chart | Every entity, every owner and percentage, who holds clinical licenses, any management company already in place | PE, family office, strategic |
| Referral map | Each current and prospective physician investor, whether they refer, how often and for which services | Physician syndicate, family office with physician co-investors, strategic |
| State footprint | Every state with a site, a licensed clinician or a payer contract, plus planned expansion states | PE, family office, strategic |
| Approvals log | Every approval each investor named at the first meeting, with the person who signs | All |
| Intermediary list | Each person or firm promised a fee, the signed agreement and the BrokerCheck result | All equity offers |
| Outreach record | Everyone contacted about the raise, how they were reached and whether you knew them beforehand | Physician syndicate, VC, family office |
| Tax model per offer | Your tax advisor's after-tax proceeds for each structure on the comparison sheet | PE, strategic, family office |
Apply it to the control sale vs minority recap example. Both offers need the ownership chart and approvals log. The PE offer adds a rollover into a platform that may use a management services structure, so the file needs the platform's entity chart too. If the family office brings physician co-investors who refer to the group, the referral map moves to the front. An offer that needs three new file items late in the process is slower than its headline suggests, so score it that way on the comparison sheet.
Take the completed file to your own attorney. Healthcare Compliance Due Diligence, Management Services Organizations, the Healthcare M&A Process Guide and Capital Raising for Healthcare Companies cover how these items show up in diligence.
Building a 100-Name Investor List and Working It in Order
Sector knowledge beats list size. Former operators underwrite a healthcare business faster because they already understand reimbursement, staffing and compliance. Build from sources that show what investors have actually done:
| Source | What it gives you | Who it finds |
|---|---|---|
| Add-on press releases in your specialty | Platform, sponsor, geography, date | PE platforms and their sponsors |
| PE firm and platform websites | Current portfolio and target specialties | PE funds and platforms |
| SEC EDGAR full-text search for Form D filings | Healthcare companies in your region that raised private capital, with named executives and directors | Founders and directors who have raised before |
| Hospital system disclosures on MSRB EMMA and system press releases | Acquisitions, affiliations and service line plans of systems that issue municipal bonds | Strategic buyers and their deal calendar |
| Subscription deal databases | Deal history, check sizes and contacts | PE, VC, family offices with recorded deals |
| Your own network and advisors | Exited founders, former health system executives, physician angels | Sector operators |
Build the list in four tiers:
| Tier | Who | Names | Contact order |
|---|---|---|---|
| 1. Best fit | Direct-investing family offices with healthcare deals, PE platforms buying in your specialty and region, healthcare VC funds at your stage | 5 to 10 | First, with the full data package |
| 2. Sector operators | Exited healthcare founders, former health system executives, physician angels | 20 to 30 | After Tier 1 responds |
| 3. Institutions | PE funds, private credit lenders, health system corporate development and venture arms | 30 to 40 | In parallel with Tier 2 |
| 4. Physician syndicate | Physicians you know personally, screened for referral relationships | Remainder | Last, once the structure is settled |
Run reverse diligence on every Tier 1 name before the first meeting. Ask for two founder references, including one where the deal went badly. Reverse Due Diligence on Healthcare Investors lists the questions.
The first message must show fit in its opening lines. Include five items:
- [ ] Specialty or product, and sites
- [ ] Trailing EBITDA, or revenue and growth rate for a healthtech company
- [ ] Amount sought
- [ ] Structure offered (control, minority, preferred, debt)
- [ ] Why this investor, by name, with a portfolio or mandate reference
Track every name in one sheet: tier, date contacted, response, next step and reason for any pass. Pass reasons are the most useful data you will collect. Three passes for the same reason, such as size, payer mix or a missing QoE, tell you what to fix before you open the next tier.
Questions owners ask
Which type of healthcare investor moves fastest?
The number of approval layers sets the pace more than the investor type. At the first meeting, ask each investor to name every approval between the first call and a signed term sheet, and who signs at each step. PE funds and hospital systems often add a quality of earnings report, committee approval or integration planning, depending on the buyer and the deal size. A lender can move quickly when cash flow is steady and documented. A family office can be quick or slow depending on its own governance, so ask rather than assume.
Can I raise money from physicians who refer patients to my business?
Sometimes. The answer depends on the structure and the facts. Referral laws can apply when a physician who refers patients to a business also owns part of it. Build a referral map of every prospective physician investor and settle the structure before anyone commits money.
Do family offices take minority stakes in healthcare companies?
Many do, but each office sets its own mandate. An office investing from the family's balance sheet is free to take a minority stake or hold for a long time, though its own policies may rule that out. An office investing through a fund, an SPV or alongside a PE sponsor takes on that vehicle's horizon and exit terms. Find out how the office invests and what it has done before you send a deck.
Should I sell control or a minority stake?
Compare cash at close against what you keep and who controls the next sale. A control sale to PE usually pays more cash today, but your rollover depends on the platform's exit. A minority recap pays less cash and leaves you in control of the remaining equity. The worked example in this guide runs both on the same business.
Do venture capital firms invest in medical practices?
Rarely. Venture capital backs healthtech, device, diagnostics and biotech companies that can grow many times over and exit through a sale or IPO. A cash-flowing practice is valued on EBITDA and fits PE, family offices, strategics or lenders. A technology business built around a practice can fit VC if the growth case is real.
How many investors should be on my outreach list?
Build the list around fit, not volume. About 100 names with a real sector connection, drawn from add-on announcements, Form D filings, hospital system disclosures and exited healthcare founders, beats a purchased database of thousands. Rank the list in tiers and contact the best-matched investors first.
Sources
- CMS National Health Expenditure fact sheet (2024 data, 2025 to 2034 projections)
- AMA Policy Research Perspective, Physician Practice Characteristics in 2024 (2024 survey data)
- AMA press release on the 2024 Physician Practice Benchmark Survey (2024 survey data)
- Becker's ASC Review reporting PESP outpatient deal data (calendar 2025)
- Becker's Hospital Review reporting Kaufman Hall hospital M&A data (2026 reporting, secondary source)
- Medscape Physician Compensation Report 2025 press release (2024 compensation data)
- SBA 7(a) loan program (program page, accessed November 2026)
- SEC EDGAR full-text search
- FINRA BrokerCheck
- U.S. Bureau of Labor Statistics, Health Care and Social Assistance industry page (accessed November 2026)
- HHS OIG List of Excluded Individuals and Entities (accessed November 2026)